Thalassemia is a chronic hemolytic disease of genetic origin. The burden of the disease is enormous, disrupting growth and quality of life. Although adequate blood transfusion and iron chelation early in life can minimize morbidities, this treatment modality is only palliative and has many problems. The ultimate goal should be aimed at cure; at present, this is achievable with allogeneic bone marrow transplantation (BMT) but feasibility is limited by scarcity of matched sibling donors. Preliminary results of allogeneic BMT with matched sibling donors in thalassemia patients revealed that children in class 3 Lucarelli had the worst outcome in terms of survival, disease-free survival, and rejection of 0.61, 0.53, and 0.16, respectively. These unsatisfactory results were largely due to a major increase in nonrejection mortality. 1 Andreani et al 2 reported that persistent mixed chimerism can be achieved and can accomplish sufficient hemoglobin levels in post-transplant thalassemia. This should make nonmyeloablative stem cell transplantation (NST) an interesting approach for thalassemia in order to overcome nonrejection mortality among class 3 patients. 3 Indeed, we have already reported a successful NST in a class 3 Lucarelli severe thalassemia patient. 4 However, the limited availability of matched sibling donors requires that alternative sources of donors be explored. We, therefore, investigated one approach with haploidentical donor in this group of patients. This approach has not been published before. The study was approved by the Ethics Committee of the Faculty of Medicine, Ramathibodi Hospital, Mahidol University and the patient consented to this procedure.
An 18-year-old girl with homozygous b-thalassemia had 97% haemoglobin F at age 7 months. She has received monthly blood transfusion since 7 months of age (a total of 200 times) and chelation therapy with desferrioxamine since 16 years of age. Prior to each blood transfusion, her hemoglobin level was 5-6 gm/dl. At the age of 7 years, she underwent splenectomy because of massive splenomegaly. She also had hepatomegaly. Prior to transplantation, the patient received a thorough physical examination and evaluation. Her serum ferritin was 3860 ng/ml. Biopsy of the liver revealed moderate to severe hepatic fibrosis and iron over load in the liver as defined by Sciot. 5 The extents of hepatomegaly, portal fibrosis, and iron overload in the liver put her into the class 3 risk category as proposed by Lucarelli et al. Our experience with NST in a class 3 Lucarelli severe thalassemia patient in the past suggests that the use of hydroxyurea for immune suppression prior to transplantation may prevent graft rejection and contribute to the success of NST in this group of patients. 4 Therefore, the patient was primed with hydroxyurea 20 mg/kg daily for 6 months prior to NST. The conditioning regimen consisted of busulfan, 2 mg/kg given orally every 12 h for 2 days; fludarabine, 35 mg/m 2 infused daily for 5 days; antilymphocyte globulin (Fresenius, HemoCare s , Germany) 5 mg/kg provided daily for 5 days, and total lymphoid irradiation administered as a single fraction of 500 cGy with shielding of the liver, lung, heart, and ovaries. 4, 6 No anti-infective prophylaxis regimen was used in this patient. Her maternal donor received subcutaneous G-CSF 10 mg/kg/day for 4 days before leukapheresis procedure. Subcutaneous venous catheter was inserted a day before leukapheresis. The donor underwent leukapheresis twice. Then, purified CD34 þ cells derived from peripheral blood stem cells were obtained with Clinimacs s and transfused at a dose of 11.0 Â 10 6 cells/kg together with additional CD3 þ cells to a total number of 1 Â 10 5 CD3 þ cells/kg. Prophylaxis regimen against graftversus-host disease comprised of mycophenolate mofetil given at a dose of 1.5 gm/day for 45 days and cyclosporin at a dose to maintain blood level of more than 200 ng/ml for 100 days.
The outcome of NST with haploidentical bone marrow is as follow. Myelosuppression was transient. The times of neutrophil engraftment was day þ 11 and of platelet engraftment was day þ 13. She received packed red cell transfusion four times (last transfusion at day þ 240), six platelet transfusions (last transfusion at day þ 12). The length of hospitalization during transplantation procedure was 50 days. She developed acute GVHD grade II (skin) and also had multiple post transplant complications that included hemorrhagic cystitis, CMV retinitis, herpes zoster, mycoplasma pneumonia, and bacterial sepsis. Nevertheless, all these complications were resolved with appropriate treatments. She also developed extensive stage of chronic GVHD (skin) but was able to recover from this complication with tracolimus and prednisolone treatment. It should be mentioned that we did not study immune reconstitution post NST.
Chimerism was documented by assay of fluorescently labeled short tandem repeats in genomic DNA. The patient achieved full (100%) donor chimerism at 1 month post NST and can maintain this full donor chimerism at 6 months and 1 year after NST. At the time of this report, 1 year and 6 months post NST, the chimerism still showed 100% of donor cells in the recipient's blood. The patient had a good quality of life with no clinical features of thalassemia. The hemoglobin level was 12 g/dl. Hemoglobin typing showed HbA 92%, F 3%, and A 2 5%.
Her serum ferritin level at 18 months post transplant was 6020 ng/ml. She therefore enrolled in our phlebotomy programme to correct iron overload after transplantation.
High nonrejection mortality and graft failure are major obstacles in the progress of marrow transplantation especially in class 2 and 3 thalassemia patients. 1 Gaziev et al 7 reported that hydroxyurea, azathioprine, and fludarabine given prior to transplantation can reduce graft failure and increase success of the second marrow transplant in patients with class 3 thalassemia. They speculated that the success of second marrow transplantation was in part due to increased immune suppression by the priming regimen. We have reported similar success of NST in the class 3 thalassemia with hydroxyurea alone. 4 This success of NST with hydroxyurea alone was duplicated in the present study. Another mechanism that reduces rejection was a large number of stem cells. Therefore, both hydroxyurea administration prior to NST and a large number of stem cells acted in concert to reduce the rejection in this type of transplantation.
NST can avoid the cytokine storm. 8 This can reduce the toxicity from transplantation procedure and contribute to reduction of nonrejection mortality. The use of the NST regimen permits engraftment of donor stem cells by creating marrow space through the graft-versus-host effect, not by myeloablative chemotherapy or radiation therapy.
Krishnamurti et al 6 and our group have reported successful NST in sickle cell disease and thalassemia. 4 The present study demonstrates that NST is also feasible with haploidentical donor in class 3 thalassemia. Graft rejection and delayed immune reconstitution were a major concern in this haploidentical setting. 9 We have succeeded in overcoming this problem by employing CD34 þ cell purification method to deplete T cells, and by adding CD3 þ cells at the time of stem cell transfusion to a total number of 1 Â 10 5 cells/kg. The exact dose of CD3 þ cells to maximize the therapy and to minimize the adverse effects remains to be determined.
In conclusion, the present study demonstrated that NST with haploidentical stem cells was well tolerated, can achieve stable engraftment, and ameliorate symptoms of severe class 3 thalassemia. The encouraging result of this pilot case is evidence for the feasibility of this method of therapy in severe thalassemia but warrants further study. 
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